Modality
mRNA
MOA
CAR-T BCMA
Target
BCMA
Pathway
T-cell
CF
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
~Oct 2020
→ ~Jan 2022
Phase 3
Apr 2022
→ Jul 2027
Phase 3Current
NCT05088634
2,942 pts·CF
2022-04→2027-07·Completed
NCT08600240
2,996 pts·CF
2025-03→TBD·Completed
5,938 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-091.3y awayPh3 Readout· CF
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2027-07-09 · 1.3y away
CF
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05088634 | Phase 3 | CF | Completed | 2942 | HAM-D |
| NCT08600240 | Phase 3 | CF | Completed | 2996 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |